Loading…
Lobbying Spend
—
Filings
56
Firms Hired
2
Active Period
1999–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Strengthening the Vaccines for Children Program Act of 2026
2026 · third_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Federal immunization and vaccine policies including changes to the ACIP and impact on the PI community; Federal funding for primary immunodeficiency research; Federal newborn screening policies; H.R. 8425, Strengthening the Vaccines for Children Program Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 8425
PI Post Acute Access Act
2026 · third_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
H.R. 8528 PI Post-Acute Access Act and policies to address access to immunoglobulin during Medicare-covered Skilled Nursing Facility admissions.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 8528
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · fourth_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Legislation to address access to immunoglobulin during Medicare-covered Skilled Nursing Facility admissions; Medicaid and budget reconciliation; H.R. 1/One Big Beautiful Bill.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · third_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Legislation to address access to immunoglobulin during Medicare-covered Skilled Nursing Facility admissions; Medicaid and budget reconciliation; H.R. 1/One Big Beautiful Bill.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · second_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Legislation to address access to immunoglobulin during Medicare-covered Skilled Nursing Facility admissions; Medicaid and budget reconciliation; H.R. 1/One Big Beautiful Bill.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 1
PI Post Acute Access Act
2024 · fourth_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
H.R. 3017, the PI Post Acute Access Act and policies pertaining to access to immunoglobulin (Ig) treatments for Medicare beneficiaries within Skilled Nursing Facilities
Client expense: — · Firm income: $20,000
Matched citations: H.R. 3017
Joe Fiandra Access to Home Infusion Act of 2023
2024 · fourth_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Funding and related issue pertaining to improving diagnostics of PI; H.R. 5397, the Joe Fiandra Access to Home Infusion Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 5397
PI Post Acute Access Act
2024 · fourth_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
H.R. 3017, the PI Post Acute Access Act and policies pertaining to access to immunoglobulin (Ig) treatments for Medicare beneficiaries within Skilled Nursing Facilities
Client expense: — · Firm income: $10,000
Matched citations: H.R. 3017
Joe Fiandra Access to Home Infusion Act of 2023
2024 · fourth_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Funding and related issue pertaining to improving diagnostics of PI; H.R. 5397, the Joe Fiandra Access to Home Infusion Act.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 5397
PI Post Acute Access Act
2024 · third_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
H.R. 3017, the PI Post Acute Access Act and policies pertaining to access to immunoglobulin (Ig) treatments for Medicare beneficiaries within Skilled Nursing Facilities
Client expense: — · Firm income: $20,000
Matched citations: H.R. 3017
Joe Fiandra Access to Home Infusion Act of 2023
2024 · third_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Funding and related issue pertaining to improving diagnostics of PI; FDA proposal to regulate Laboratory Developed Tests (LDTs); H.R. 5397, the Joe Fiandra Access to Home Infusion Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 5397
PI Post Acute Access Act
2024 · second_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
H.R. 3017, the PI Post Acute Access Act and policies pertaining to access to immunoglobulin (Ig) treatments for Medicare beneficiaries within Skilled Nursing Facilities
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3017
Joe Fiandra Access to Home Infusion Act of 2023
2024 · second_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Funding and related issue pertaining to primary immunodeficiency disease; FDA proposal to regulate Laboratory Developed Tests (LDTs); H.R. 5397, the Joe Fiandra Access to Home Infusion Act.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 5397
PI Post Acute Access Act
2024 · first_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
H.R. 3017, the PI Post Acute Access Act and policies pertaining to access to immunoglobulin (Ig) treatments for Medicare beneficiaries within Skilled Nursing Facilities
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3017
PI Post Acute Access Act
2023 · fourth_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
H.R. 3017, the PI Post Acute Access Act and policies pertaining to access to immunoglobulin (Ig) treatments for Medicare beneficiaries within Skilled Nursing Facilities; implementation of permanent Medicare in-home IVIG bundled payment.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3017
HELP Copays Act
2023 · fourth_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Opportunities to increase funding to support research into primary immunodeficiency diseases; H.R. 830 and S. 1375, the HELP Copays Act; Proposed FDA rule re: Laboratory Developed Test and implications for the PI community.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 830
Opportunities to increase funding to support research into primary immunodeficiency diseases; H.R. 830 and S. 1375, the HELP Copays Act; Proposed FDA rule re: Laboratory Developed Test and implications for the PI community.
Client expense: — · Firm income: $30,000
Matched citations: S. 1375
PI Post Acute Access Act
2023 · third_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
H.R. 3017, the PI Post Acute Access Act and policies pertaining to access to immunoglobulin (Ig) treatments for Medicare beneficiaries within Skilled Nursing Facilities; implementation of permanent Medicare in-home IVIG bundled payment.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 3017
Opportunities to increase funding to support research into primary immunodeficiency diseases; H.R. 830 and S. 1375, the HELP Copays Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 830
Opportunities to increase funding to support research into primary immunodeficiency diseases; H.R. 830 and S. 1375, the HELP Copays Act.
Client expense: — · Firm income: $20,000
Matched citations: S. 1375
PI Post Acute Access Act
2023 · second_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
H.R. 3017, the PI Post Acute Access Act and policies pertaining to access to immunoglobulin (Ig) treatments for Medicare beneficiaries within Skilled Nursing Facilities; implementation of permanent Medicare in-home IVIG bundled payment.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3017
HELP Copays Act
2023 · second_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
Opportunities to increase funding to support research into primary immunodeficiency diseases; H.R. 830 and S. 1375, the HELP Copays Act.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 830
Opportunities to increase funding to support research into primary immunodeficiency diseases; H.R. 830 and S. 1375, the HELP Copays Act.
Client expense: — · Firm income: $30,000
Matched citations: S. 1375
Preserving Patient Access to Home Infusion Act
2020 · fourth_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
H.R. 7839 - Continuing Access to In-Home IVIG Act; S. 3457, H.R. 6218 - Preserving Patient Access to Home Infusion Act; COVID-19 response and beneficiary access to home infusion care as a result of the PHE.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6218
Continuing Access to In-Home IVIG Act
2020 · fourth_quarter · Firm: FAEGRE DRINKER BIDDLE & REATH LLP
H.R. 7839 - Continuing Access to In-Home IVIG Act; S. 3457, H.R. 6218 - Preserving Patient Access to Home Infusion Act; COVID-19 response and beneficiary access to home infusion care as a result of the PHE.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 7839
Source: Senate LDA